We at UCSF take your care seriously. Click here for COVID-19 information

University of California San Francisco

A test often used in breast cancer has been found to also identify which patients with aggressive prostate cancer will benefit from hormonal therapy.  Dr. Felix Feng, one of the senior authors on an article published in JAMA Oncology, said “We’re hopeful that the biomarkers will prove to be a robust predictor of hormone treatment success, so we can increase survival of even the most aggressive cases and at the same time limit hormone treatment to those patients most likely to benefit from it.”  Read the UCSF News Release here.